- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: MM-141 | MM141
Compound class: Antibody
Comment: Istiratumab (MM-141) is a fully human bispecific monoclonal antibody co-targeting the IGF-I receptor (IGF-IR) and epidermal growth factor receptor ERBB3 that was developed by Merrimack Pharmaceuticals to block tumour survival signals [1,3,5].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|In November 2014, the US FDA granted Orphan Designation to MM-141 for the treatment of pancreatic cancer. Click here to link to ClinicalTrials.gov's full list of MM-141 trials. As of mid 2018 it appears that development of MM-141 has been terminated as it failed ot meet primary and secondary endpoints in Phase 2 trial in pancreatic cancer ptients.|
|Mechanism Of Action and Pharmacodynamic Effects|
|The IGF-1R and ERBB3 signaling pathways are reported to be implicated in the adoption of escape mechanisms which can develop in response to multiple targeted cancer therapies [2,4]. MM-141 treatment blocks IGF-IR and ERBB3 signaling and prevents cells from adapting to use redundant PI3K/AKT/mTOR survival pathways  which can result in enabling downstream resistance mechanisms.|